Found review
Updated
A named obesity-medicine team, and a $49 price with two conditions
Five named physicians including a former medical director of the obesity-medicine board — and a headline $49 that requires both a twelve-month commitment and commercial insurance, on a plan billed every four weeks.
We may earn a commission if you sign up through our links, at no cost to you. How we make money.
Key details
- Advertised price
- "$49/mo" is the figure attached to the non-GLP-1 Generics Plan. It appears nowhere on Found's plans-and-pricing page; the real table is an image inside the binding Offer Terms.
- Billing details
- $89 a month with commercial insurance, or $149 cash-pay, for the Generics Plan bought a month at a time — billed every four weeks. $49 is the twelve-month insured rung and $99 the twelve-month cash rung. On the compounded GLP-1 plan the Offer Terms give $199 insured and $299 cash month to month, falling to $149 and $199 at twelve months.
- Pharmacy
- Not named — but the category is claimed specifically, about Found's own supply rather than in the abstract: its compounded-semaglutide page states that Found "partners exclusively with 503A-licensed pharmacies", and the medication is described as third-party tested for potency, purity and sterility. That is the category without the facility — half an answer, but the more useful half. The clinical team is named in full: Dr Rekha Kumar MD MS (senior medical advisor, former ABOM medical director), Dr Jonathan Larson MD MBA (medical director), Dr Judith Korner MD PhD of Columbia, Dr Shebani Sethi MD of Stanford and Dr Kyu Rhee MD MPP — with Found disclosing on its own pages that Dr Kumar does not interact directly with Found patients.
- Availability
- Forty-one states are listed as having insurance plans accepted, and the same page contradicts itself twice: New Mexico renders an "available plans" panel while being absent from the 41-state selector, and California appears in the accepted list while its own panel reads "No plans available for this state."
- Review coverage
- Separate review. Not ranked as an NAD+ provider and not eligible to be: Found's entire formulary is fourteen weight-loss medications — GLP-1 injectables, two oral GLP-1s, and Contrave, metformin, topiramate and zonisamide. There is no NAD+, no peptide, no B-12, nothing for energy, cognition or longevity. It appears only in the clearly labeled GLP-1 section of our NAD+-for-weight-loss page, where the point is that NAD+ does not cause weight loss and GLP-1 medications do.
Our verdict
Found's clinical team is its strength, and its pricing page is the least reliable thing about it. The team is real and named: Dr Rekha Kumar MD MS, a former medical director of the American Board of Obesity Medicine, sits as senior medical advisor alongside a medical director and physicians from Columbia and Stanford — and Found itself discloses that Dr Kumar does not interact directly with patients, a qualifier most companies leave for someone else to find. Against that, the numbers disagree with each other. The "$49" attached to the non-GLP-1 generics plan requires both a twelve-month commitment and commercial insurance; month to month it is $89 with insurance and $149 cash-pay. And the binding Offer Terms contradict the marketing page on three of four cells for the compounded GLP-1 plan. If NAD+ is what brought you here, the short answer is that Found does not sell it or anything like it.
NAD+ evidence
The route question this site normally asks does not apply here, and forcing it would be worse than saying so plainly: Found sells no NAD+ in any form, so there is no NAD+ delivery route to assess. Its formulary is fourteen weight-loss medications — compounded semaglutide, tirzepatide and liraglutide, brand Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Victoza and Trulicity, the oral GLP-1s Foundayo and Rybelsus, and the non-GLP-1 orals Contrave, metformin, topiramate and zonisamide. That class is exactly what NAD+ therapy is not: large randomized controlled trials against hard weight and cardiometabolic endpoints. The qualifier that applies to every compounder applies here too — those trials tested the FDA-approved branded products, and a compounded copy inherits the molecule but not the trial data. Read against our own evidence pages, the summary is that GLP-1 drugs cause weight loss, NAD+ does not, and nothing on Found's menu addresses energy, cognition or longevity at all.
Pricing and fees
- Advertised price
- "$49/mo" is the figure attached to the non-GLP-1 Generics Plan. It appears nowhere on Found's plans-and-pricing page; the real table is an image inside the binding Offer Terms.
- Payment terms
- $89 a month with commercial insurance, or $149 cash-pay, for the Generics Plan bought a month at a time — billed every four weeks. $49 is the twelve-month insured rung and $99 the twelve-month cash rung. On the compounded GLP-1 plan the Offer Terms give $199 insured and $299 cash month to month, falling to $149 and $199 at twelve months.
- Pricing details
- Three stacked, and the third is the one nobody expects. First, $49 needs two conditions at once — a twelve-month commitment AND commercial insurance — and neither is attached to the figure where it is advertised. Second, billing is every four weeks, so a year is thirteen charges rather than twelve. Third, Found's "12 months" is 48 weeks, which is about eleven calendar months of coverage — so the commitment that unlocks the lowest rung buys less time than its name implies. Separately, the binding Offer Terms and the public pricing page disagree on three of the four compounded-GLP-1 cells; the Offer Terms are the document that binds.
Additional fees
- Billing every four weeks means thirteen cycles a year, not twelve
- Membership is refundable only within three days or before the first consult
- Medications and lab kits are non-refundable once shipped, and renewals are non-refundable
- Cancellation requires at least 48 hours' notice before renewal
Prices are from Found's own website and can change without notice.
Who it may suit
May suit you if
- Weight loss is your actual goal and you want a named, credentialed obesity-medicine team
- You want a non-GLP-1 oral path — Contrave, metformin, topiramate or zonisamide — priced separately from the injectables
- You have commercial insurance and will commit to a twelve-month plan, which is what the cheapest advertised figure actually requires
- You want a company that discloses the limits of its own medical advisors rather than implying they see patients
Consider another option if
- You want NAD+, a peptide, B-12 or anything for energy or cognition — Found's formulary is fourteen weight-loss drugs and nothing else
- You want the advertised price: $49 needs both a year's commitment and insurance, and month to month is $89 or $149
- You want the marketing page and the binding terms to say the same thing — on the compounded GLP-1 plan they disagree on three of four cells
- You live in a state whose panel and whose selector disagree — New Mexico and California each contradict themselves on Found's own page
What’s included
- Consultation
- Yes — a clinician reviews the case and prescribes, inside a membership rather than as a per-visit charge. The membership is refundable only within three days or before the first consult, so the window to change your mind closes early.
- Lab testing
- Lab kits are sold and are named in the refund policy as non-refundable once shipped. Nothing published makes them a gate on starting.
- Follow-up care
- Included in the membership; the plan renews on its own cycle and cancellation needs 48 hours' notice.
- Clinical support
- Found's own framing is behavioral: coaching and habit tooling sit alongside the medication rather than the medication being the whole offer.
- Supplies
- Not itemized on the pages we read.
- Shipping
- Not priced separately on the pages we read.
Limitations and policy details
Found's binding Offer Terms contradict its own public pricing page on three of the four cells of the compounded GLP-1 plan. The pricing page advertises $99 and $169 at twelve months and $199 and $289 month to month; the Offer Terms — the document you actually agree to — say $149 and $199 at twelve months and $199 and $299 month to month. Only one of the four figures matches. And the real table is not text on a page: it is an image inside the terms, so a screen reader cannot read it and a search cannot find it. Beside that sits the "$49", quoted as a monthly rate, which requires both a twelve-month commitment and commercial insurance — while the twelve months in question is 48 weeks, roughly eleven calendar months, on a plan billed every four weeks, so the year contains thirteen charges. Each detail alone is small; together they are the difference between the number advertised and the number paid. The state page also contradicts itself twice on the same screen.
Other considerations
- The binding Offer Terms disagree with the public pricing page on three of four compounded-GLP-1 cells
- The real price table is an image inside the terms — unreadable by a screen reader and unfindable by search
- The advertised "$49" requires both a twelve-month commitment and commercial insurance; month to month it is $89 insured or $149 cash
- Billing is every four weeks (thirteen cycles a year) and "12 months" is 48 weeks, about eleven calendar months of coverage
- The state page contradicts itself twice — New Mexico is absent from the selector but shows a plans panel, and California is in the accepted list while its own panel says no plans are available
- No dispensing pharmacy is named, only the 503A category
- It sells no NAD+, no peptide and nothing for energy or cognition
Cost calculators
How this site makes money
We may earn a commission when you buy a product or start care through our links, at no extra cost to you. Affiliate partners appear first in our provider comparison. Read the full disclosure.
Every figure on this page comes from Found’s own site, and prices change without notice. Read every provider review.
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.